Oxford Immunotec Global PLC (NASDAQ:OXFD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Saturday.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

A number of other brokerages have also recently commented on OXFD. Cowen and Company reiterated a “buy” rating and issued a $22.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Piper Jaffray Companies reiterated a “buy” rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. BTIG Research began coverage on Oxford Immunotec Global PLC in a report on Thursday, September 28th. They issued a “buy” rating and a $21.00 target price for the company. Robert W. Baird reiterated a “buy” rating and issued a $20.00 target price on shares of Oxford Immunotec Global PLC in a report on Wednesday, November 1st. Finally, ValuEngine cut Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Oxford Immunotec Global PLC has a consensus rating of “Hold” and a consensus target price of $19.75.

Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at $13.25 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.51 and a current ratio of 4.72. Oxford Immunotec Global PLC has a 1-year low of $12.24 and a 1-year high of $19.51.

TRADEMARK VIOLATION WARNING: “Oxford Immunotec Global PLC (OXFD) Stock Rating Lowered by Zacks Investment Research” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/05/oxford-immunotec-global-plc-oxfd-stock-rating-lowered-by-zacks-investment-research.html.

In related news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $15.82, for a total transaction of $47,460.00. Following the completion of the transaction, the director now owns 18,000 shares in the company, valued at approximately $284,760. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 70,739 shares of company stock valued at $1,167,597. 8.11% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of OXFD. American International Group Inc. boosted its holdings in Oxford Immunotec Global PLC by 7.1% during the 1st quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after acquiring an additional 904 shares during the period. Nationwide Fund Advisors boosted its holdings in Oxford Immunotec Global PLC by 1.9% during the 1st quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock valued at $213,000 after acquiring an additional 254 shares during the period. Parkwood LLC boosted its holdings in Oxford Immunotec Global PLC by 12.9% during the 2nd quarter. Parkwood LLC now owns 12,799 shares of the company’s stock valued at $215,000 after acquiring an additional 1,465 shares during the period. Voya Investment Management LLC boosted its holdings in Oxford Immunotec Global PLC by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock valued at $224,000 after acquiring an additional 1,845 shares during the period. Finally, Alliancebernstein L.P. purchased a new position in Oxford Immunotec Global PLC during the 2nd quarter valued at $247,000. Institutional investors own 79.21% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.